Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib

Br J Haematol. 2020 Jul;190(1):e48-e51. doi: 10.1111/bjh.16709. Epub 2020 May 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aminopyridines / therapeutic use*
  • Female
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Male
  • Middle Aged
  • Mutation
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / enzymology
  • Myeloproliferative Disorders / genetics
  • Treatment Outcome
  • Triazines / therapeutic use*

Substances

  • Aminopyridines
  • Triazines
  • enasidenib
  • Isocitrate Dehydrogenase
  • isocitrate dehydrogenase 2, human